References
- Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
- Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
- Trinkaus M, Simmons C, Myers J, et al. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 2010;18:197-203
- Rader M, Goessl C, Cong Z. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2012;18:74-5; author reply 75–6